Irinotecan and immunotherapy for resectable pancreatic cancer
Part of Cancer clinical trials.
This trial tests adding a new immunotherapy drug (addebelizumab) to standard chemotherapy for people with pancreatic cancer that can be removed by surgery. The goal is to see if the combination shrinks tumors more effectively before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- Your pancreatic cancer is confined to the pancreas and major blood vessels are not significantly involved, so surgery to remove it is possible.
- You have not received any previous cancer treatment (chemotherapy, radiation, immunotherapy, or targeted therapy).
- You have at least one tumor that can be measured on a scan.
- You are generally active and able to care for yourself (ECOG performance status 0 or 1).
- Your kidney, liver, and bone marrow function must be adequate, as determined by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) given before and after surgery for people with pancreatic cancer that is at high risk of coming back but can still be surgically removed. The goal is to see if this treatment helps improve outcomes.
This trial tests a new immunotherapy drug (adebrelimab) combined with a standard chemotherapy cocktail (NALIRIFOX) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination shrinks or controls the cancer better than chemo alone.
This trial tests a new immunotherapy for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. It may be an option if you have already tried at least one previous treatment or if you have not had any treatment yet, depending on the study group.
This trial tests a combination of three chemotherapy medicines (liposomal irinotecan, oxaliplatin, and tegafur) given after surgery to remove pancreatic cancer. The goal is to see if this treatment helps prevent the cancer from coming back.
This trial tests a combination of two chemotherapy drugs (irinotecan liposome and capecitabine) for people with pancreatic cancer that has spread or cannot be removed by surgery and has gotten worse after initial treatment. The goal is to see if this combination can help slow the disease.
This trial compares two combinations of chemotherapy drugs for people with advanced pancreatic cancer whose first treatment stopped working. The study tests whether adding oxaliplatin and bevacizumab to liposomal irinotecan works better than a standard combination.
Hear when a new Neoadjuvant Chemotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.